Equal HIV-1 decay kinetics in HSV-2-infected and HSV-2-uninfected clinical trial participants treated with antiretroviral therapy

J Acquir Immune Defic Syndr. 2012 May 1;60(1):68-71. doi: 10.1097/QAI.0b013e31824bed3f.

Abstract

Herpes simplex virus-2 increases HIV-1 viral load and may augment HIV-1 transmission probability. To test the hypothesis that lower HIV-1 clearance rates in HSV-2-infected persons may account for this higher HIV-1 viral load, we studied 149 participants from 3 ACTG viral dynamic studies (A315, A5160s, and A5166s). Though HIV-1 viral load was 0.19 logs higher in HSV-2-positive versus HSV-2-negative persons, first and second phase clearance rates during antiretroviral therapy were equal between participants in these 2 groups.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active*
  • Coinfection / drug therapy
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / isolation & purification*
  • Herpes Genitalis / complications*
  • Herpesvirus 2, Human / isolation & purification
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome
  • Viral Load*

Substances

  • Anti-HIV Agents